Human Anti-ERBB2 Recombinant Antibody (clone H2-18) (CAT#: HPAB-0679YY)

This product is a recombinant human antibody that recognizes (both natural and recombinant) human ERBB2.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
Inhib

Figure 1 H2-18 and GDC-0941 synergistically inhibited the growth of both trastuzumab-sensitive and -resistant breast cancer cell lines.

Figure 1 H2-18 and GDC-0941 synergistically inhibited the growth of both trastuzumab-sensitive and -resistant breast cancer cell lines.

CCK8 assay was used to compare cell proliferation of the breast cancer cell lines SKBR-3 upon indicated treatments.

Wang, L., Yu, X., Wang, C., Pan, S., Liang, B., Zhang, Y., ... & Yang, Y. (2017). The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer. Oncotarget, 8(32), 52877.

ELISA

Figure 2 H2-18 plus GDC-0941 inhibits the ErbB2 signaling in breast cancer cell lines HCC-1954.

Figure 2 H2-18 plus GDC-0941 inhibits the ErbB2 signaling in breast cancer cell lines HCC-1954.

Quantification of Akt phosphorylation in HCC-1954 cells following indicated drug treatments. HCC-1954 cells treated with control IgG, H2-18, GDC-0941, and GDC-0941 plus H2-18 for 4h were lysed immediately, and the concentrations of phospho-Akt in the cell lysates were determined by a commercially available ELISA kit.

Wang, L., Yu, X., Wang, C., Pan, S., Liang, B., Zhang, Y., ... & Yang, Y. (2017). The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer. Oncotarget, 8(32), 52877.

FC

Figure 3 H2-18 and GDC-0941 in combination induced more cell death than agents alone.

Figure 3 H2-18 and GDC-0941 in combination induced more cell death than agents alone.

Cell death induced by control IgG, H2-18, GDC-0941, and GDC-0941 plus H2-18 in breast cancer cell line SKBR-3 was examined by flow cytometry using Annexin V/PI double staining detecting kit.

Wang, L., Yu, X., Wang, C., Pan, S., Liang, B., Zhang, Y., ... & Yang, Y. (2017). The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer. Oncotarget, 8(32), 52877.

Inhib

Figure 4 H2-18 plus GDC-0941 suppressed the in vivo growth of HCC-1954 xenografts.

Figure 4 H2-18 plus GDC-0941 suppressed the in vivo growth of HCC-1954 xenografts.

Tumor volume of HCC-1954 breast tumor xenografts were calculated after treatment with control IgG (10 mg/kg, twice a week, intravenously), H2-18 (10 mg/kg, twice a week, intravenously), GDC-0941 (100 mg/kg, daily, orally), and GDC-0941 (100 mg/kg, daily, orally) plus H2-18 (10 mg/kg, twice a week, intravenously).

Wang, L., Yu, X., Wang, C., Pan, S., Liang, B., Zhang, Y., ... & Yang, Y. (2017). The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer. Oncotarget, 8(32), 52877.

Cyt

Figure 5 H2-18 potently induces apoptosis in ErbB2-overexpressing breast cancer cell lines.

Figure 5 H2-18 potently induces apoptosis in ErbB2-overexpressing breast cancer cell lines.

Cell death induced by control IgG, trastuzumab, pertuzumab, trastuzumab plus pertuzumab, and H2-18 in high-ErbB2-expressing (BT-474) was measured by flow cytometry using Annexin V/PI detecting kit.

Lu, Q., Wang, L., Zhang, Y., Yu, X., Wang, C., Wang, H., ... & Wang, Y. (2016). An anti-ErbB2 fully human antibody circumvents trastuzumab resistance. Oncotarget, 7(41), 67129.

Cyt

Figure 6 H2-18-induced cell death is RIP1-dependent programmed necrosis.

Figure 6 H2-18-induced cell death is RIP1-dependent programmed necrosis.

The effect of pan caspase inhibitor Z-VADFMK and autophagy inhibitor bafilomycin A1 on H2-18-induced cell death in HCC-1954 cells.

Lu, Q., Wang, L., Zhang, Y., Yu, X., Wang, C., Wang, H., ... & Wang, Y. (2016). An anti-ErbB2 fully human antibody circumvents trastuzumab resistance. Oncotarget, 7(41), 67129.

EM

Figure 7 H2-18-induced cell death is RIP1-dependent programmed necrosis.

Figure 7 H2-18-induced cell death is RIP1-dependent programmed necrosis.

TEM images of HCC-1954 cells treated with control IgG, trastuzumab, pertuzumab, pertuzumab plus trastuzumab, and H2-18 for 48 hours.

Lu, Q., Wang, L., Zhang, Y., Yu, X., Wang, C., Wang, H., ... & Wang, Y. (2016). An anti-ErbB2 fully human antibody circumvents trastuzumab resistance. Oncotarget, 7(41), 67129.

Apop

Figure 8 H2-18-induced cell death is RIP1-dependent programmed necrosis.

Figure 8 H2-18-induced cell death is RIP1-dependent programmed necrosis.

The effect of Nec-1 on H2-18-induced cell death in HCC-1954 cells.

Lu, Q., Wang, L., Zhang, Y., Yu, X., Wang, C., Wang, H., ... & Wang, Y. (2016). An anti-ErbB2 fully human antibody circumvents trastuzumab resistance. Oncotarget, 7(41), 67129.

Apop

Figure 9 ROS and JNK take part in H2-18-induced programmed cell death.

Figure 9 ROS and JNK take part in H2-18-induced programmed cell death.

The effect of JNK inhibitor SP600125 or ROS scavenger NAC on H2-18-induced cell death in HCC-1954 cells.

Lu, Q., Wang, L., Zhang, Y., Yu, X., Wang, C., Wang, H., ... & Wang, Y. (2016). An anti-ErbB2 fully human antibody circumvents trastuzumab resistance. Oncotarget, 7(41), 67129.

FC

Figure 10 ROS and JNK take part in H2-18-induced programmed cell death.

Figure 10 ROS and JNK take part in H2-18-induced programmed cell death.

JC-1 staining was used to measure the mitochondrial membrane potential in HCC-1954 cells treated with H2-18.

Lu, Q., Wang, L., Zhang, Y., Yu, X., Wang, C., Wang, H., ... & Wang, Y. (2016). An anti-ErbB2 fully human antibody circumvents trastuzumab resistance. Oncotarget, 7(41), 67129.


Specifications

  • Host Species
  • Human
  • Derivation
  • Phage display library
  • Type
  • Human IgG
  • Specificity
  • Human
  • Species Reactivity
  • Human
  • Clone
  • H2-18
  • Applications
  • Inhib, ELISA, FC, Cyt, EM, Apop
  • Related Disease
  • Cancer

Product Property

  • Purity
  • >95% as determined by SDS-PAGE and HPLC analysis
  • Concentration
  • Please refer to the vial label for the specific concentration.
  • Buffer
  • PBS
  • Preservative
  • No preservatives
  • Storage
  • Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Applications

  • Application Notes
  • The ERBB2 antibody has been reported in applications of Inhibition, Enzyme-linked Immunosorbent Assay, Flow Cytometry, Cytotoxicity, Electron Microscopy, Apoptosis.
    Inhib: 10 mg/kg.

Target

  • Alternative Names
  • NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu;

Related Resources

  • Related Diseases
  • Related Signaling Pathways

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone H2-18"

See other products for "ERBB2"

Intrabody

CAT Product Name Application Type
IAB-B008(A) Recombinant Anti-human ERBB2 Intrabody [(D-Arg)9] IF, FC, FuncS scFv-(D-Arg)9
IAB-B008(G) Recombinant Anti-human ERBB2 Intrabody [+36 GFP] WB, ICC, FuncS scFv-(+36GFP)
IAB-B008(T) Recombinant Anti-human ERBB2 Intrabody [Tat] ICC, Neut, FuncS scFv-Tat

Chimeric Antibody

CAT Product Name Application Type
TAB-761 Anti-ERBB2 Recombinant Antibody (Margetuximab) IF, IP, Neut, FuncS, ELISA, FC, WB IgG1 - kappa
TAB-049CT Anti-Human HER2/neu Recombinant Antibody (ChA21) IHC, Inhib, WB, Activ, FC Chimeric antibody (mouse/human)
TAB-049CT-S(P) Anti-Human HER2/neu Recombinant Antibody scFv Fragment (ChA21) WB Chimeric antibody (mouse/human)
TAB-049CT-F(E) Anti-Human HER2/neu Recombinant Antibody Fab Fragment (ChA21) WB Chimeric antibody (mouse/human)

Humanized Antibody

CAT Product Name Application Type
TAB-H70 Anti-Human ERBB2 Recombinant Antibody (Trastuzumab Emtansine) ELISA, IP, FC, FuncS, Neut, IF, ICC IgG1 - kappa
TAB-053 Anti-Human ERBB2 Recombinant Antibody (Pertuzumab) FuncS, IF, Neut, ELISA, FC, IP, WB IgG1 - kappa
TAB-050CT-S(P) Anti-Human HER2/neu Recombinant Antibody scFv Fragment (HuA21) ELISA, WB Humanized antibody
TAB-053CT-S(P) Human Anti-ERBB2 Recombinant Antibody; scFv Fragment (TAB-053CT-S(P)) ELISA, Inhib, FC Humanized scFv
TAB-054CT-S(P) Humanized Anti-Human HER2/neu Recombinant Antibody scFv Fragment ELISA, Inhibition, FC Humanized antibody

Immunotoxin

CAT Product Name Application Type
AGTO-G022E Anti-ERBB2 immunotoxin 4D5 (scFv)-PE Cytotoxicity assay, Function study
AGTO-G022D Anti-ERBB2 immunotoxin 4D5 (scFv)-DT Cytotoxicity assay, Function study
AGTO-G022G Anti-ERBB2 immunotoxin 4D5 (scFv)-Gel Cytotoxicity assay, Function study
AGTO-G022R Anti-ERBB2 immunotoxin 4D5 (scFv)-RTA Cytotoxicity assay, Function study
AGTO-G022S Anti-ERBB2 immunotoxin 4D5 (scFv)-Sap Cytotoxicity assay, Function study

Fab Glycosylation

Deglycosylated Antibody (Non-glycosylated IgGs)

CAT Product Name Application Type
Gly-177LC Recombinant Anti-Human ERBB2 Antibody (Non-glycosylated) ELISA Humanized antibody

Chicken IgY Antibody

CAT Product Name Application Type
BRD-0195MZ Chicken Anti-ERBB2 Polyclonal IgY WB Chicken antibody
BRD-0695MZ Chicken Anti-ERBB2 Polyclonal IgY WB Chicken antibody
BRD-0779MZ Chicken Anti-ErbB2 Polyclonal IgY ICC, IF, IHC, IP Chicken antibody

Blocking Antibody

CAT Product Name Application Type
NEUT-737CQ Mouse Anti-ERBB2 Recombinant Antibody (clone 7.16.4) Block, IP, IF, FC Mouse IgG2a

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-468CQ Afuco™ Anti-ERBB2 ADCC Recombinant Antibody (Timigutuzumab), ADCC Enhanced ELISA, IHC, FC, IP, IF, FuncS ADCC enhanced antibody
AFC-TAB-053 Afuco™ Anti-ERBB2 ADCC Recombinant Antibody (Pertuzumab), ADCC Enhanced FuncS, IF, Neut, ELISA, FC, IP ADCC enhanced antibody
AFC-TAB-761 Afuco™ Anti-ERBB2 ADCC Recombinant Antibody (Margetuximab), ADCC Enhanced IF, IP, Neut, FuncS, ELISA, FC ADCC enhanced antibody
AFC-TAB-005 Afuco™ Anti-ERBB2 ADCC Recombinant Antibody (Trastuzumab), ADCC Enhanced FC, IP, ELISA, Neut, FuncS, IF ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for HPAB-0679YY. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare